# Neuphoria Therapeutics Inc. (NEUP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $7M  
**Price:** $4.49 (+1.58%)

> Neuphoria Therapeutics Inc. is a biotech company engaged in the research and development of novel therapeutics, primarily focused on addressing unmet medical needs in mental health. The company's work is pivotal within the biotech sector, as it explores innovative solutions for conditions such as depression and anxiety disorders, which affect millions worldwide. By leveraging cutting-edge technologies and collaborative research, Neuphoria Therapeutics aims to create effective treatments that can transform the landscape of mental health care. The influence of Neuphoria in the biotech industry is significant, as it contributes to the growing demand for specialized and advanced treatment options in the healthcare sector. Functioning in a space where breakthroughs can significantly enhance quality of life, Neuphoria Therapeutics is positioned as a key player in the push toward mental health advancements. As it progresses in its developmental pipeline, the company's activities remain closely watched by stakeholders in pharmaceuticals, healthcare providers, and patient communities.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $16M | — | -$1M | -$369,632 | $-0.23 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $29M | $10M | $19M | $14M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $77,229 | — | — |
| 2024 | -$15M | — | — |
| 2023 | -$15M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/NEUP)